Komori
Occurring Fact2183Linical Co.,Ltd.Information and Communications, Services and Others

Notice Regarding a Large Order

株式会社リニカルグループ secured a large order worth US$20.4 million (¥3,212 million) from a US biotech company. The impact of the order on results has already been incorporated into the earnings forecast for the fiscal year ending March 2027.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
20.4
million US dollars (¥3,212 million)
Wording
Conditional
How definitive the wording is.

Securing a large order from a business partner

Subject Entity

株式会社リニカル (the Company Group)

This disclosure10/09/2026
Cause

FDA operations were curtailed following the partial shutdown of US government agencies last year, delaying contract signings.

Accounting period in which recognized

Fiscal year ending March 2027

Impact on Earnings Forecast

The impact on results for the fiscal year ending March 2027 has already been incorporated into the earnings forecast announced on 15 May 2026.

Outlook

The Company will continue its sales activities to secure additional orders.

Event that occurred
ItemDetails
Event nameSecuring a large order from a business partner
Subject Entity株式会社リニカル (the Company Group)
CauseFDA operations were curtailed following the partial shutdown of US government agencies last year, delaying contract signings.
Accounting period in which recognizedFiscal year ending March 2027
Impact on Earnings ForecastThe impact on results for the fiscal year ending March 2027 has already been incorporated into the earnings forecast announced on 15 May 2026.
OutlookThe Company will continue its sales activities to secure additional orders.
Items this document does not state (19)
Date of occurrenceDate recognized / date notice receivedTarget Locations / ProductsAmount of Impact on Business PerformanceType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

FDA operations were curtailed following the partial shutdown of US government agencies last year, delaying contract signings. However, order-taking activity in the US is moving toward normalisation, and inquiries about outsourcing development projects are increasing.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Large Order | Linical Co.,Ltd. (2183) timely disclosure | Komori